Balchem Corp. Q1 2007 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2007. Balchem Corporation develops, manufactures, and distributes specialty performance ingredients for food, nutritional, pharmaceutical, animal health, and medical device sterilization industries. The company operates through three segments: Specialty Products, Encapsulated/Nutritional Products, and BCP Ingredients.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Sales | $27,599 | $24,597 |
| Gross Profit | $9,741 | $8,222 |
| Gross Margin % | 35.3% | 33.4% |
| Operating Income | $5,342 | $4,469 |
| Net Earnings | $3,441 | $2,858 |
| Diluted EPS | $0.19 | $0.16 |
| Cash from Operations | $3,197 | $4,199 |
| Cash & Equivalents (End) | $3,690 | $6,346 |
| Total Debt (Current + Long-term) | $29,000 | $0 |
Note: All dollar amounts in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12.2% year-over-year, driven by volume growth in all three segments. The BCP Ingredients segment saw a 17.2% increase, and Encapsulated/Nutritional Products rose 17.5%.
- Profitability: Net earnings increased 20.4% to $3.441 million. Gross margin percentage improved to 35.3% due to favorable product mix, increased production volumes, and lower raw material prices.
- Acquisition Activity: The company acquired certain choline chloride business assets from Chinook Global Limited on March 16, 2007, for approximately $29 million in debt plus inventory value. This significantly increased intangible assets and debt levels compared to the prior year.
- Debt Structure: Total debt increased from zero in Q1 2006 to $29 million in Q1 2007, consisting of a new term loan used to fund the Chinook acquisition.
Outlook, Risks, and Unusual Items
- Subsequent Acquisition: On April 30, 2007 (post-period), the company acquired the methylamines and choline chloride business of Akzo Nobel Chemicals S.p.A. in Italy for a provisional price of approximately $6.281 million.
- Financing: A new $29 million term loan (LIBOR + 1%) and a $6 million revolving credit facility were established to fund acquisitions. The term loan matures in March 2010.
- Accounting Changes: The company adopted FASB Interpretation No. 48 (FIN 48) regarding uncertainty in income taxes, resulting in a non-cash charge of $291,000 to beginning retained earnings.
- Stock-Based Compensation: Estimated share-based compensation expense for 2007 is approximately $1.568 million.
- Risks: Management notes that forward-looking statements involve risks, including market conditions and the ability to integrate acquisitions. The company has limited exposure to foreign currency risk as sales are generally billed in U.S. dollars.
Investor Verification Checklist
- Verify the final purchase price and working capital adjustments for the April 30, 2007 Akzo Nobel acquisition.
- Monitor the integration progress and revenue contribution of the Chinook Global Limited assets acquired in March 2007.
- Review the impact of the new $29 million term loan on future interest expense and cash flow coverage.
- Confirm the realization of projected cost savings and synergies from recent acquisitions.
- Track the status of the $6 million revolving credit facility and any potential draws.